Liposem 2

✔️ How does Saroglitazar work?

Saroglitazar is a novel dual Peroxisome Proliferator-Activated Receptor (PPAR) agonist with predominant PPAR-α activity and moderate PPAR-γ activity. Through activation of these nuclear receptors, Saroglitazar exerts both lipid-modifying and glucose-lowering effects.

✔️ Effects on Lipid Metabolism

Activation of PPAR-α:

• Enhances hepatic fatty acid oxidation
• Reduces hepatic triglyceride synthesis and secretion
• Promotes clearance of triglyceride-rich lipoproteins from plasma
• Increases lipoprotein lipase (LPL) activity
• Decreases the production of apolipoprotein C-III, an inhibitor of LPL
• Reduces circulating triglycerides, VLDL, and LDL cholesterol
• Increases synthesis of apolipoproteins A-I and A-II, leading to higher HDL cholesterol levels

✔️ Effects on Glucose Metabolism

Activation of PPAR-γ:

• Improves insulin sensitivity
• Enhances glucose uptake and utilization
• Reduces hepatic glucose production
• Increases expression of genes involved in carbohydrate and lipid metabolism, including adiponectin, fatty acid transport proteins, and lipoprotein lipase
• Decreases postprandial free fatty acid levels
• Improves insulin-mediated suppression of hepatic glucose output

These combined actions contribute to improved glycemic control and reduced metabolic burden on the liver and skeletal muscles.

✔️ Side Effects

In controlled Phase III clinical trials, the most commonly reported adverse reactions (occurring in more than 2% of patients) included:

• Gastritis
• Asthenia (weakness or fatigue)
• Pyrexia (fever)

Most adverse events were mild to moderate in severity and generally did not require discontinuation of therapy.

As with all medicines, adverse event rates observed in clinical trials may differ from those seen in routine clinical practice.

✔️ Drug Interactions

In vitro studies suggest that Saroglitazar has a low potential for clinically significant drug-drug interactions.

Saroglitazar does not significantly inhibit the following cytochrome P450 (CYP) enzymes:

• CYP1A2
• CYP2C9
• CYP2C19
• CYP2D6
• CYP3A4

Additionally, Saroglitazar has not demonstrated clinically relevant induction of CYP3A4 activity in laboratory studies.

Although dedicated clinical interaction studies have not been conducted, available evidence indicates a low likelihood of significant CYP-mediated interactions at therapeutic doses.

✔️ Overdose

No cases of Saroglitazar overdose have been reported during clinical studies.

In the event of overdose:

• Provide supportive and symptomatic treatment
• Monitor vital signs and clinical status
• Institute appropriate medical management based on the patient's condition

There is no known specific antidote for Saroglitazar overdose.

✔️ Pregnancy and Lactation

Pregnancy

Pregnancy Category C

There are no adequate and well-controlled studies evaluating the use of Saroglitazar during pregnancy. Therefore, its safety in pregnant women has not been established.

Saroglitazar should only be used during pregnancy if the expected benefit to the mother outweighs the potential risk to the fetus.

Patients who become pregnant while receiving treatment should consult their physician promptly.

Lactation

It is not known whether Saroglitazar is excreted into human breast milk.

Because of the potential for adverse effects in nursing infants, use of Saroglitazar is not recommended during breastfeeding.

✔️ Liposem is contraindicated in patients with:

• Known hypersensitivity to Saroglitazar or any component of the formulation.

✔️ Saroglitazar should be used with caution in patients with:

• Impaired liver function
• Renal impairment
• History of myopathy or muscle disorders
• Type 2 diabetes with underlying cardiac disease
• Previous or existing congestive heart failure

Patients should be monitored for:

• Fluid retention
• Excessive edema
• Rapid unexplained weight gain
• Signs and symptoms of congestive heart failure

Any sudden increase in body weight should prompt evaluation for fluid accumulation and cardiovascular complications.

✔️ Storage:

• Store below 25°C in a dry place.
• Protect from light and moisture.
• Keep out of the reach of children.